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Abstract 
 
Crohn’s disease (CD) is a chronic inflammatory disorder characterized 
by periods of clinical remission alternating with periods 
of relapse defined by recurrent clinical symptoms. Persistent 
inflammation is believed to lead to progressive bowel 
damage over time, which manifests with the development 
of strictures, fistulae and abscesses. These disease complications 
frequently lead to a need for surgical resection, which 
in turn leads to disability. So CD can be characterized as a 
chronic, progressive, destructive and disabling disease. In 
rheumatoid arthritis, treatment paradigms have evolved beyond 
partial symptom control alone toward the induction 
and maintenance of sustained biological remission, also 
known as a ‘treat to target’ strategy, with the goal of improving 
long-term disease outcomes. In CD, there is currently no 
accepted, well-defined, comprehensive treatment goal that 
entails the treatment of both clinical symptoms and biologic 
inflammation. It is important that such a treatment concept 
begins to evolve for CD. A treatment strategy that delays or 
halts the progression of CD to increasing damage and disability 
is a priority. As a starting point, a working definition 
of sustained deep remission (that includes long-term biological 
remission and symptom control) with defined patient 
outcomes (including no disease progression) has been proposed. 
The concept of sustained deep remission represents 
a goal for CD management that may still evolve. It is not clear 
if the concept also applies to ulcerative colitis. Clinical trials 
are needed to evaluate whether treatment algorithms that 
tailor therapy to achieve deep remission in patients with CD 
can prevent disease progression and disability. 
  
 Introduction 
 
Crohn’s disease (CD) is a chronic, progressive, destructive 
and ultimately disabling disease [1] . In other 
chronic destructive diseases such as rheumatoid arthritis 
(RA), treatment paradigms have evolved beyond partial 
symptom control alone toward the induction and maintenance 
of sustained biological remission, also known as 
a ‘treat to target’ strategy, with the goal of improving 
long-term disease outcomes i.e. reduced structural damage 
and disability [2] . In CD, there is currently no accepted 
well-defined, comprehensive treatment goal that requires 
the treatment of both clinical symptoms and biologic 
inflammation; it is important that such a treatment 
concept begins to evolve. Patients may potentially benefit 
by experiencing a ‘deep’ remission beyond the control of 
clinical symptoms, which might ultimately impact on 
important outcomes such as the need for surgery and the 
development of disability. Similarly, this concept may be 
useful when designing the next generation of clinical trials 
that could determine if treating beyond symptoms to 
deep remission can change the natural history of the disease. 
 
 
 
Rationale for Exploring the Concept of 
Deep Remission in CD 
 
The characterization of CD as a progressive, destructive 
disease that leads to irreversible bowel damage has 
become better recognized through longitudinal followup 
studies of large cohorts of CD patients. In 2002, Louis 
et al. [3] and Cosnes et al. [4] demonstrated that 74% of 
patients with CD had a nonpenetrating, nonstricturing 
phenotype at diagnosis, and that 60% of patients progressed 
to stricturing and/or penetrating lesions in the 
long term. Recently, the results from these referral center 
studies have been confirmed in a cohort based on a North 
American population [5] , showing that the natural history 
of CD is a dynamic process, leading to irreversible 
bowel damage and intestinal resection in the large majority 
of patients. Overall, the cumulative risk of surgery in 
CD patients is 50% after 10 years of evolution, with no 
dramatic change in recent years [6] . These studies reflect 
the outcomes of current treatment paradigms, which are 
based on the induction of symptomatic response and remission 
followed by maintenance of symptomatic remission. 
As the majority of patients experience disease progression 
and accumulation of bowel damage over time 
with this treatment paradigm, it would be attractive to 
develop an alternative where patients are treated to 
achieve a composite end point comprising both clinical 
and biological remission. The goal would be to block the 
progression of CD and to prevent damage progression. 
  
 Lessons from Other Chronic and Destructive 
Inflammatory Diseases 
 
There are similarities between CD and other therapy 
areas. In hypertension, type 2 diabetes and RA, a failure 
to treat early and effectively can lead to serious complications 
and disability. Disease management has evolved 
over time towards a ‘treat to target’ approach to achieve 
‘tight control’. Several studies have shown that this approach 
leads to improved outcomes compared to conventional 
care. In the TICORA (Tight Control of Rheumatoid 
Arthritis) study, which allocated outpatients with 
RA to either intensive management (aiming for sustained, 
tight control of disease activity) or conventional 
care, patients in the intensive-management group experienced 
improved control of disease activity, reduced radiographic 
disease progression, improved physical function 
and a better quality of life [7] . Similar benefits have 
been reported in other diseases. The early improvement 
of blood pressure control in patients with both type 2 diabetes 
and hypertension was associated with a reduced 
risk of complications [8] . Tight blood pressure control reduced 
morbidity and mortality in patients with hypertension [9] . 
 
What Is Deep Remission in CD? 
 
Deep remission in CD is an evolving concept and there 
is currently no definition that is widely agreed upon. At 
its most fundamental level, deep remission is a state of 
remission with little or no risk of disease progression. If 
accepted, this definition likely implies an absence of biological 
evidence of inflammation. Most physicians would 
agree that clinical remission (symptom control) and endoscopic 
remission (also known as mucosal healing) 
would appear to be vital components of deep remission. 
However, it is still under debate whether complete mucosal 
healing offers any substantial benefit over partial mucosal 
healing with a low level of residual endoscopic activity, 
and if there is also a need for radiographic transmural 
healing as demonstrated by computed tomography 
or magnetic resonance imaging enterography. There is an 
increasing interest in the utility of these biomarkers for 
monitoring disease activity. Biomarkers are indeed good 
candidates for inclusion as a component of deep remission. 
Ideally, they could replace mucosal healing and radiographic 
healing as surrogate measures of biological 
remission. However, studies are still needed to demonstrate 
that they are reliable and adequate surrogate measures. 
An important point to consider is that the treatment 
goal should probably be different in patients with early 
versus late disease due to the progressive nature of CD, as 
is the case in RA. Patients diagnosed late in the CD course 
who have already experienced a disease complication or 
required surgery may not be capable of achieving a state 
where there is a complete absence of clinical symptoms 
(due to irreversible structural damage). Several sub-analyses 
of clinical studies have suggested that higher clinical 
and endoscopic remission rates may be achieved in patients 
with early disease defined by time from diagnosis [10, 11] . 
Based on these principles, a working definition of 
deep remission has been proposed. In patients with no 
bowel damage or disability, deep remission is the resolution 
of one or more objective measures of inflammation 
(endoscopy, imaging and markers) and of symptoms, preventing 
damage and disability. In patients with existing 
damage and disability, deep remission is the resolution of 
one or more objective measures of inflammation (endoscopy, 
imaging and markers) and the improvement of 
symptoms, preventing further damage and disability and 
reverse damage if possible (unpubl. data). 
 
Is Deep Remission Achievable? 
 
Even though there are many available data regarding 
clinical remission or mucosal healing across clinical trials, 
very few studies have looked at composite end points. 
Recent data from the EXTEND (Extend the Safety and 
Efficacy of Adalimumab through Endoscopic Healing) 
study of adalimumab show that sustained deep remission 
can be achieved with an anti-TNF antibody. EXTEND 
was a 1-year trial comparing the efficacy of adalimumab 
versus placebo in inducing and maintaining mucosal 
healing [12] . The study included a prespecified secondary 
analysis of deep remission, defined as clinical remission 
[CD activity index (CDAI) < 150 points] and mucosal 
healing (absence of mucosal ulceration). In this study, 
19.4% of patients receiving adalimumab every other week 
achieved deep remission at 1 year (compared to none of 
the patients receiving placebo; p < 0.001) (unpubl. data). 
As anticipated, patients with a shorter disease duration 
tended to have a better chance of achieving deep remission 
at 1 year: 33% of patients with a disease duration ≤ 2 
years compared to 25% for ≤ 5 years and 16% for > 5 
years. We had the opportunity to investigate deep remission 
according to different definitions in the STORI (Infliximab 
Discontinuation in Crohn’s Disease Patients in 
Stable Remission on Combined Therapy with Immunosuppressors) 
trial [13] . This study looked at the impact of 
maintenance infliximab withdrawal in patients with CD. 
One hundred and fifteen patients (with a median disease 
duration of 7.8 years) were treated with combined scheduled 
infliximab and azathioprine therapy for > 1 year. 
When infliximab was stopped, they had to be in steroid steroidfree 
clinical remission for > 6 months. Among the 115 patients 
in clinical remission, 39 (34%) had a CDAI < 150 
and a CD endoscopic index of severity (CDEIS) of 0, 98 
(85%) had a CDAI < 150 and a CDEIS < 4, 83/109 (76%) 
had a CDAI < 150 and a CRP < 5 mg/l, and 63/85 (74%) 
had a CDAI < 150 and a stool calprotectin level < 250 mg/g 
(unpubl. data). 
  
 Is Deep Remission Desirable? 
 
In RA, studies have shown that structural deterioration 
is closely related to clinical disease activity but that 
radiographic progression may occur in patients in symptomatic 
remission. Several explanations have been provided: 
synovitis and damage may be independent processes, 
clinical measures are not sensitive to detect low 
disease activity and remission criteria are not stringent 
enough. Very few studies have looked at the impact of 
deep remission in CD and no study has compared the 
benefit of deep remission over clinical or endoscopic remission 
only. 
The achievement of deep remission was associated 
with improved outcomes in EXTEND (unpubl. data). Patients 
who achieved early deep remission had fewer hospitalizations 
and CD-related surgeries after 1 year than 
patients who did not achieve it. These patients also had a 
better quality of life and their productivity and activity in 
the workplace were less impaired. Patients with early 
deep remission experienced fewer dose escalations, and 
early deep remission was associated with health-care cost 
savings of approximately USD 9,000 at 1 year. In STORI, 
several parameters that may define deep remission such 
as a CDEIS of 0, a calprotectin level > 250 mg/g and an 
hsCRP < 5 mg/l were associated with a reduced risk of 
relapse when infliximab was stopped [13] . 
 
Does the Concept of Deep Remission Apply to 
Ulcerative Colitis? 
 
Until now, major end points of natural history studies 
of ulcerative colitis (UC) have been colectomy rates, cancer, 
disease activity and disease extension. The deleterious 
consequences of ongoing inflammation in the colonic 
physiology have not been adequately studied [14] . Being 
only a mucosal disease, UC is not typically accompanied 
by the stricturing and fistulizing complications that can 
be seen in CD; hence, the tendency among physicians to 
consider it a less progressive disease [14] . This attitude 
results in a reluctance to introduce more potent treatments 
earlier in the course of disease, even if this approach 
has been shown to have better outcomes. 
Evaluation of UC severity and activity is based on clinical 
symptoms and on endoscopic indices of inflammation. 
In most clinical trials and in clinical practice, 
therapeutic goals for UC have translated into achieving 
mucosal healing. The impact of mucosal healing was 
demonstrated in the ACT (Active Ulcerative Colitis) trials. 
Infliximab-treated patients with lower endoscopy 
subscores at week 8 were less likely to progress to colectomy 
over 54 weeks of follow-up (p = 0.0004) [15] . This 
trend was not observed in placebo-treated patients (p = 0.47). 
Moreover, patients with lower endoscopy subscores 
at week 8 achieved better clinical outcomes for symptomatic 
remission, corticosteroid-free symptomatic remission 
and mucosal healing, and were more likely to discontinue 
corticosteroids at weeks 30 and 54 (p < 0.0001 for 
infliximab and p < 0.01 for placebo). Nevertheless, it has 
not yet been shown that treating patients beyond clinical 
remission in order to get a state of deep clinical and full 
endoscopic remission is indeed associated with better 
outcomes. 
 
 
 
Conclusion 
 
Even though the concept of deep remission is appealing 
in IBD, there are still many uncertainties regarding 
its definition and clinical relevance. Prospective studies 
such as the CALM study are ongoing to demonstrate that 
a tight control approach using biomarkers targeting deep 
remission is superior to a classic approach based on clinical 
symptoms. Caution is nevertheless advised: in diabetes 
patients, it was shown that a very tight blood glucose 
control was actually associated with an increased mortality [16] . 
A careful evaluation of the risk/benefit ratio is 
important. 
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